P0157 Do cytoreductive treatments improve symptomatic adverse local events and urinary patients reported outcome measures in de novo metastatic prostate cancer? Analysis from a phase II randomised study (IP2-ATLANTA)

M.J. Connor; Taimur Tariq Shah; S.J. Morris; Johanna Sukumar; Francesca Fiorentino; C. Heath; G. Horan; N. Johnson; V. Khoo; B. Khoubehi; N. Klimowska-Nassar; Stephen A. Mangar; J. McGrath; C. Nohpal de la Rosa; A. Smith; D. Price; B. Rai; N Sarwar; J.N. Staffurth; H. Tam; Kamal Thippu Jayaprakash; Mathias H. Winkler; Tim J. Dudderidge; H.U. Ahmed

doi:10.1016/s0302-2838(26)01065-1

P0157 Do cytoreductive treatments improve symptomatic adverse local events and urinary patients reported outcome measures in de novo metastatic prostate cancer? Analysis from a phase II randomised study (IP2-ATLANTA)

European Urology 2026

View at publisher

Authors: M.J. Connor, Taimur Tariq Shah, S.J. Morris, Johanna Sukumar, Francesca Fiorentino, C. Heath, G. Horan, N. Johnson, V. Khoo, B. Khoubehi, N. Klimowska-Nassar, Stephen A. Mangar

+12 more

J. McGrath, C. Nohpal de la Rosa, A. Smith, D. Price, B. Rai, N Sarwar, J.N. Staffurth, H. Tam, Kamal Thippu Jayaprakash, Mathias H. Winkler, Tim J. Dudderidge, H.U. Ahmed

DOI: 10.1016/s0302-2838(26)01065-1

Cited by: 0

Fields of Study & Subjects

Prostate Cancer Treatment and Research Prostate Cancer Diagnosis and Treatment Bone health and treatments

Publication details

Journal / source: European Urology
Volume: 89
Pages: S1–S2
Publication date: 13 February 2026
Language: EN